Amgen and Daiichi Sankyo ink biosimilar agreement

15-07-2016

Biotechnology company Amgen and Japan-based Daiichi Sankyo have agreed a deal that will allow for the commercialisation of nine biosimilars in Japan.


Amgen, Daiichi Sankyo, biosimilars, licensing

LSIPR